Healthcare, Pharma & Life Sciences

Piramal Pharma Solutions Triples Microbiology Lab Capacity in Lexington

Image
Piramal Pharma Solutions Triples Microbiology Lab Capacity in Lexington

Lexington – October 06, 2026 -- Piramal Pharma Solutions (PPS) has opened a new microbiology laboratory at its Lexington site that more than triples existing testing space and is expected to cut testing times by up to 50%.

New Grade A isolator doubles sterility testing capacity at the site

The facility's centerpiece is a fully integrated, Grade A sterility testing isolator housed within a dedicated suite with a Grade C background environment, a major upgrade from the previously non-classified testing area. The isolator supports both open and closed filtration methods and allows multiple samples to be processed simultaneously, doubling the site's sterility testing capacity.

Qurin Launches Qatra Kit, Boosts Urine DNA Yield 7.6-Fold

Leiden – – October 06, 2026 -- Qurin has launched the Qatra Genomic DNA Extraction Lab Kit (RUO), a Research Use Only product capable of processing urine volumes up to 400 mL, a full void, compared with the 40-50 mL standard in conventional laboratory workflows.

Qatra kit delivers 7.6-fold increase in DNA yield in internal studies

In internal studies, average DNA yields rose 7.6-fold as sample volume increased from 50 mL to 400 mL. Qurin states this volume expansion could allow researchers to recover substantially more biomarker material from a single sample, particularly relevant when target DNA is present at low concentrations.

Perspectum Names Warren Cresswell CEO, Ex-Prometheus Labs Chief

Image
Perspectum Names Warren Cresswell CEO, Ex-Prometheus Labs Chief

Oxford, England – October 06, 2026 -- Perspectum, an Oxford-based precision health company, has appointed Warren Cresswell as Chief Executive Officer, bringing more than 25 years of diagnostics and medical device leadership to the firm's push into liver and cardiometabolic disease imaging. The placement was executed by Slone Partners, a nationwide executive search firm serving life sciences and healthcare organizations.

Cresswell previously led Nestlé-owned Prometheus Laboratories through a growth phase

Cresswell served as President and CEO of Prometheus Laboratories, a Nestlé Health Science company, where he directed the diagnostics business through a period of significant expansion. He has built commercial and CLIA-certified laboratory infrastructure supporting FDA-cleared diagnostics in the United States and most recently served as CEO of a precision oncology company.

Portland Research Site Marks 50 Years Behind Every Alzheimer's Drug Class

Image
Portland Research Site Marks 50 Years Behind Every Alzheimer's Drug Class

Portland – October 06, 2026 -- Headlands Research - Summit Portland is marking 50 years of operation in 2026, having contributed clinical research to every FDA-approved class of Alzheimer's disease medication brought to market since 1993. The site, founded in 1976, has conducted more than 500 clinical trials in partnership with pharmaceutical companies and contract research organizations (CROs).

Vision To Learn Hits 300,000 Glasses Milestone, Expands LA Program

Image
Vision To Learn Hits 300,000 Glasses Milestone, Expands LA Program

Los Angeles – – October 06, 2026 -- Vision To Learn has provided 300,000 children in California with free glasses, a milestone marked today at 24th Street Elementary School alongside the launch of a new initiative to outfit every child in Los Angeles Unified's Community Schools.

Nonprofit marks 300,000-glasses milestone with LA Unified officials

Founder Austin Beutner, California Teachers Association President David Goldberg, and LA Unified Superintendent Andrés E. Chait joined the event. Vision To Learn operates mobile vision clinics staffed by licensed eye care professionals, delivering screenings, exams and glasses directly at schools in low-income communities at no cost to families.

Mozart Therapeutics Data Backs MTX-101 for Type 1 Diabetes

Image
Mozart Therapeutics Data Backs MTX-101 for Type 1 Diabetes

SEATTLE – October 06, 2026 -- Mozart Therapeutics presented three new data sets on its lead candidate MTX-101 at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held September 28–October 06, 2026, in Milan, Italy, advancing the bispecific antibody toward a planned Phase 2a trial in Stage 3 type 1 diabetes with enrollment targeted for the first half of 2027.

Phase 1a/b data show MTX-101 is well tolerated and may affect C-peptide levels

The first presentation detailed safety, pharmacokinetic and pharmacodynamic results from a Phase 1a/b study in healthy adults and type 1 diabetes patients. Clinical data collected to date indicate MTX-101 has been relatively safe and well tolerated, with early signals suggesting a positive effect on C-peptide levels in patients with Stage 3 disease.

BioMarin Names Cara Bauer Chief People Officer, Succeeding Wireman

Image
BioMarin Names Cara Bauer Chief People Officer, Succeeding Wireman

San Rafael, Calif. – October 06, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) appointed Cara Bauer, Ph.D., as Executive Vice President, Chief People Officer, effective Oct. 5, 2026, succeeding Amy Wireman, who is retiring after nearly 14 years at the company.

Bauer arrives with 25 years of HR leadership across biotech and technology

Bauer joins BioMarin from Kyverna Therapeutics, Inc., where she served as Chief Human Resources Officer starting October 2024. She previously held the role of global head of human resources at Kite, a Gilead company, and led HR for the entertainment division at Riot Games. Earlier in her career she held HR leadership positions at Netflix, Amgen and Novo Nordisk.

Epcoritamab-R-CHOP Combo Cuts DLBCL Progression Risk 51% in Phase 3

North Chicago / Copenhagen – October 06, 2026 -- AbbVie and Genmab A/S reported that epcoritamab combined with standard R-CHOP chemotherapy reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients, based on topline Phase 3 data.

Trial hits statistical significance with hazard ratio of 0.49

The Phase 3 EPCORE DLBCL-2 study showed a hazard ratio of 0.49 (95% CI 0.36-0.67; p-value less than 0.0001) for progression-free survival in patients with an International Prognostic Index (IPI) score of 2 to 5. For the trial's primary endpoint population, patients with IPI scores of 3 to 5, the hazard ratio was also 0.49 (95% CI 0.35-0.69; p-value less than 0.0001).

101 Mobility Ranks No. 296 on 2026 Franchise Times Top 400

Image
101 Mobility Ranks No. 296 on 2026 Franchise Times Top 400

Wilmington, N.C. – October 05, 2026 -- 101 Mobility has secured rank No. 296 on the 2026 Franchise Times Top 400, marking its second consecutive year on the list of largest U.S.-based franchise systems ranked by global systemwide sales.

101 Mobility grows to over 150 locations nationwide

The home accessibility and mobility franchise now operates more than 150 U.S. locations, with owners providing stairlifts, wheelchair ramps, patient lifts, bathroom safety equipment, and elevators through sales, rentals, installation, and service.

Franchise Times ranking draws on five-month sales research

The Franchise Times Top 400 ranking results from an annual five-month research and reporting process that the publication positions as the most credible and objective franchise sales ranking available.

Blue Zones Names Ex-Baptist Health CEO Brett McClung as New CEO

Image
Blue Zones Names Ex-Baptist Health CEO Brett McClung as New CEO

Minneapolis – October 05, 2026 -- Blue Zones has appointed Brett McClung as Chief Executive Officer and President, tapping a healthcare executive with more than two decades of experience to lead the longevity research company's next growth phase.

McClung brings direct Blue Zones Project implementation experience from two major health systems

McClung most recently served as President and CEO of Baptist Health in Jacksonville, Florida, where he championed bringing Blue Zones Project to the city. Before that, he was Executive Vice President and Chief Operating Leader of Texas Health Resources, serving as executive sponsor of Blue Zones Project in Fort Worth.